A Phase 1/2 interventional study of Ribociclib 400mg and Ribociclib 600mg in Breast Cancer, sponsored by Nagoya City University. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Nagoya City University · Phase 1/2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing ribociclib in Breast Neoplasms — 17 open to participants now, 31 under way, 8 of them phase 3. ribociclib · Breast Neoplasms.
Among the 70 studies testing ribociclib in Breast Neoplasms, this one is the 44th largest by planned enrollment, is one of 3 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 20 of the 30 other live ones, and was the 64th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →17 of the 70 studies testing ribociclib in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Natera, Inc. · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+ · Women only
American Society of Clinical Oncology · Sites in United States
Ages 60+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–99
By country, each count listing its studies:
ribociclib: first FDA approval 2017 (KISQALI), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, ribociclib is the treatment under test here. Read study by study →
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 34 · Phase 3 19 · Phase 4 5
First in 2013; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 116 across the 70 interventional studies. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 70 have an industry lead sponsor. The 10 most frequent:
Nagoya City University is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Nagoya City University has 4 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies testing ribociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04055493Phase 3Women's Cancer Study Group GmbHAdj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | 2027-07-31 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT06481956Zheng YabingT-DM1 Combined With CDK4/6 Inhibitor Ribociclib | 2027-01-10 |
| NCT05996107University of Michigan Rogel Cancer CenterStudy of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer | 2027-02 |
| NCT01872260Novartis PharmaceuticalsStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | 2027-02-26 |
Add all 7 to your calendar (.ics) → With an account.
Among the 70 studies testing ribociclib in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic or recurrent breast cancer. The trial aims to evaluate the efficacy (specifically, overall response rate) and safety of this combination in the Japanese patient population. Nagoya City University is the sponsor of this trial, with funding provided by Novartis Pharma K.K..
Study Design and Endpoints: The trial is structured into two parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ER positive: ≥1% positive cells or Allred score ≥3.
PgR positive: ≥1% positive cells or Allred score ≥3.
HER2 negative: IHC 0, 1+, or 2+ with no ISH amplification.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
phase 1b cohort 1
Drug: Ribociclib 400mg
phase 1b cohort 2
Drug: Ribociclib 600mg
Drug: Ribociclib 600mg
phase 1b cohort 1
Phase 1b cohort 2
phase 2
This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Phase 1b part: Dose Limiting Toxicity
Time frame: From enrollment to the end of treatment at 4 weeks
Phase 2 part: Overall response rate
Time frame: From enrollment to the end of treatment at 24 weeks
Phase 1b part: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: From enrollment to the end of treatment at 4 weeks
Phase 1b part: Peak Plasma Concentration (Cmax)
Time frame: From enrollment to the end of treatment at 4 weeks
Phase 2 part: Overall Response Rate
Time frame: From enrollment to the end of treatment at 24 weeks
Phase 2 part: PFS
Time frame: Time Frame: From enrollment to the end of treatment at 24 weeks
Phase 2 part: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: From enrollment to the end of treatment at 24 weeks
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.
Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 47 months is below that.
Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribociclib
Nagoya City University